<article>
  <type>blog</type>
  <title>DARPA Awards Medical Nano Platform Contract</title>
  <author/>
  <date>January 17, 2013</date>
  <departments>
    <department>Defense Operations</department>
    <department>Acquisition and Contracting</department>
  </departments>
  <tags>
    <tag>Agentase LLC</tag>
    <tag>Nano</tag>
    <tag>DARPA</tag>
    <tag>Contract Awards</tag>
  </tags>
  <abstract></abstract>
  <text>Agentase LLC, Pittsburgh, Pa., has been awarded an $11,206,720 cost contract. The work will support DARPA's In Vivo (within the living) Nanoplatforms program (IVN). IVN seeks to develop new classes of adaptable nanoparticles for persistent, distributed, unobtrusive physiologic and environmental sensing as well as the treatment of physiologic abnormalities, illness and infectious disease. The contracting activity is DARPA, Arlington, Va., (HR0011-14-C-0030).
	.</text>
  <imgalttext>
  </imgalttext>
</article>
